

# BHUTAN

Number of new cases

**638**

Number of deaths

**480**

Number of prevalent cases (5-year)

**1 246**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	419 618	368 326	787 944
<b>Incidence*</b>			
Number of new cancer cases	356	282	638
Age-standardized incidence rate	90.5	84.5	87.6
Risk of developing cancer before the age of 75 years (cum. risk %)	10.2	9.6	10.0
<b>Top 3 leading cancers (ranked by cases)**</b>	Stomach Oesophagus Liver	Cervix uteri Stomach Lung	Stomach Lung Cervix uteri
<b>Mortality*</b>			
Number of cancer deaths	280	200	480
Age-standardized mortality rate	72.4	61.2	67.2
Risk of dying from cancer before the age of 75 years (cum. risk %)	8.5	7.4	8.0
<b>Top 3 leading cancers (ranked by deaths)**</b>	Stomach Oesophagus Liver	Stomach Cervix uteri Lung	Stomach Lung Oesophagus
<b>Prevalence*</b>			
5-year prevalent cases	633	613	1 246



## Top 5 most frequent cancers\*\*

**Males**




Total: 356

Rank	Cancer site	Number of cases	Percent
1st	Stomach	78	21.9%
2nd	Oesophagus	27	7.6%
3rd	Liver	26	7.3%
4th	Lung	26	7.3%
5th	Colorectum	20	5.6%
-	Others	179	50.3%

Number of new cases in 2022, males, all ages

**Females**




Total: 282

Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	49	17.4%
2nd	Stomach	37	13.1%
3rd	Lung	25	8.9%
4th	Ovary	20	7.1%
5th	Oesophagus	19	6.7%
-	Others	132	46.8%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 638

Rank	Cancer site	Number of cases	Percent
1st	Stomach	115	18.0%
2nd	Lung	51	8.0%
3rd	Cervix uteri	49	7.7%
4th	Oesophagus	46	7.2%
5th	Liver	33	5.2%
-	Others	344	53.9%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Stomach	115	1	18.0	1.9	103	1	21.5	1.7	169	21.5
Lung	51	2	8.0	0.87	51	2	10.6	0.87	68	8.6
Cervix uteri	49	3	7.7	1.4	26	5	5.4	0.74	139	37.7
Oesophagus	46	4	7.2	0.79	46	3	9.6	0.79	75	9.5
Liver	33	5	5.2	0.54	33	4	6.9	0.54	44	5.6
Colorectum	30	6	4.7	0.50	20	6	4.2	0.37	75	9.5
Lip, oral cavity	22	7	3.4	0.40	13	11	2.7	0.28	55	7.0
Ovary	20	8	3.1	0.61	14	8	2.9	0.46	53	14.4
Leukaemia	20	8	3.1	0.21	16	7	3.3	0.18	56	7.1
Breast	16	10	2.5	0.50	8	15	1.7	0.28	47	12.8
Hypopharynx	14	11	2.2	0.25	5	18	1.0	0.11	25	3.2
Pancreas	14	11	2.2	0.27	14	8	2.9	0.27	13	1.7
Larynx	14	11	2.2	0.23	9	14	1.9	0.19	35	4.4
Brain CNS	14	11	2.2	0.22	14	8	2.9	0.22	41	5.2
Gallbladder	13	15	2.0	0.25	12	12	2.5	0.21	21	2.7
Nasopharynx	12	16	1.9	0.21	11	13	2.3	0.19	33	4.2
Oropharynx	10	17	1.6	0.24	8	15	1.7	0.22	24	3.1
NHL	9	18	1.4	0.19	8	15	1.7	0.17	25	3.2
Thyroid	6	19	0.94	0.09	0	24	0.00	0.00	18	2.3
Prostate	5	20	0.78	0.12	3	20	0.63	0.00	9	2.1
Corpus uteri	4	21	0.63	0.14	0	24	0.00	0.00	12	3.3
Penis	4	21	0.63	0.15	2	21	0.42	0.05	12	2.9
Bladder	4	21	0.63	0.07	4	19	0.83	0.07	10	1.3
Kidney	2	24	0.31	0.04	1	23	0.21	0.03	5	0.63
Multiple myeloma	2	24	0.31	0.05	2	21	0.42	0.05	5	0.63
Salivary glands	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
Melanoma	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
Mesothelioma	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
Kaposi sarcoma	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
Vulva	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
Vagina	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
Testis	0	26	0.00	0.00	0	24	0.00	0.00	0	0.00
<b>All cancers</b>	<b>638</b>	-	-	<b>10.0</b>	<b>480</b>	-	-	<b>8.0</b>	<b>1 246</b>	-
<b>All cancers excl. NMSC</b>	<b>630</b>	-	-	<b>9.8</b>	<b>478</b>	-	-	<b>8.0</b>	<b>1 222</b>	-

## Data source and methods

### Incidence

**Country-specific data source:** No data  
**Method:** No data: the rates are those of neighbouring countries or registries in the same area

[Click here to see detailed data source and methods](#)



### Mortality

**Country-specific data source:** Survival estimates  
**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and methods](#)

### Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021 Feb 4. doi:10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *Int J Cancer*. 2021 Apr 5. doi:10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

